

International standardization of diagnostic criteria for vasospastic angina

John F. Beltrame¹, Filippo Crea², Juan Carlos Kaski³, Hisao Ogawa^{4,5}, Peter Ong⁶, Udo Sechtem⁶, Hiroaki Shimokawa⁷, and C. Noel Bairey Merz^{8*}, On Behalf of the Coronary Vasomotion Disorders International Study Group (COVADIS)

¹The Queen Elizabeth Hospital Discipline of Medicine, University of Adelaide, Central Adelaide Local Health Network, Adelaide, South Australia, Australia; ²Institute of Cardiology, Catholic University of the Sacred Heart, Rome, Italy; ³Cardiovascular and Cell Sciences Research Institute, St George's, University of London, London, UK; ⁴Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; ⁵National Cerebral and Cardiovascular Center, Suita, Japan; ⁶Department of Cardiology, Robert-Bosch-Krankenhaus, Stuttgart, Germany; ⁷Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan; and ⁸Barbra Streisand Women's Heart Center, Cedars-Sinai Heart Institute, Cedars-Sinai Medical Center, 127 S. San Vicente Blvd Suite A3206, Los Angeles, CA, USA

Received 13 April 2015; revised 20 June 2015; accepted 24 June 2015; online publish-ahead-of-print 5 August 2015

The Coronary Vasomotion Disorders International Study Group (COVADIS) was established to develop international standards for the diagnostic criteria of coronary vasomotor disorders. The first symposium held on the 4–5 September 2013 addressed the criteria for vasospastic angina, which included the following (i) nitrate-responsive angina, (ii) transient ischaemic electrocardiogram changes, and (iii) documented coronary artery spasm. Adoption of these diagnostic criteria will improve the clinical diagnosis of this condition and facilitate research in this field.

Keywords

Coronary artery disease • Ischaemic heart disease • Coronary artery spasm • Vasospastic angina

More than 55 years ago, Prinzmetal detailed the clinical and electrocardiographic manifestations of a disorder thought to be due to epicardial coronary artery spasm, which he referred to as variant angina.¹ Subsequently, these patients were shown to have inducible coronary artery spasm and the term vasospastic angina (VSA) was coined. Except for the recently published Japanese Circulation Society guidelines^{2,3} and a brief summary in the European Society of Cardiology Stable Coronary Artery Disease Guidelines,⁴ there are no universal diagnostic criteria for VSA, which has impaired the progress in understanding and diagnosing this disorder. The objective of this paper is to establish international diagnostic criteria for VSA, to improve clinical diagnosis and facilitate research.

The term VSA should be considered as a broad diagnostic category including both documented spontaneous episodes of angina pectoris produced by coronary artery spasm as well as those induced during provocative spasm testing protocols. Although it may potentially co-exist with coronary microvascular disorders and/or structural coronary artery disease, VSA is a clinical entity that is centred on the hyper-reactivity of large coronary arteries to vasoconstrictor stimuli.⁵ The importance of diagnosing VSA relates to: (i) the major adverse events associated with this disorder including sudden cardiac death,⁶ acute myocardial infarction,⁷ and syncope,⁸ which may occur before the diagnosis of VSA is considered⁹; (ii) the potential to prevent these adverse events by

avoiding potential coronary artery spasm precipitants (e.g. vasoconstrictors) and the use of established effective therapies (calcium channel blockers and nitrates).

Table 1 summarizes the diagnostic criteria as proposed by the Coronary Vasomotion Disorders International Study Group (COVADIS). This group was established to internationally unify the diagnostic criteria for coronary vasomotor disorders, with the first COVADIS symposium held on the 4–5 September 2013 to address the VSA criteria. As detailed in Table 1 and discussed further, VSA diagnosis involves three considerations: (i) classical clinical manifestations of VSA, (ii) documentation of myocardial ischaemia during spontaneous episodes, (iii) demonstration of coronary artery spasm, while the extent of evidence sub-classifies VSA into either 'definitive' or 'suspected' VSA (Table 1).

Clinical manifestations

The hallmark feature of VSA is rest angina that promptly responds to short-acting nitrates. The anginal symptoms may exhibit a circadian pattern, be precipitated by hyperventilation but not usually exertion, and typically suppressed by calcium channel blockers (Table 1). Smoking is an established predisposing risk factor for VSA, whereas diabetes and hypertension do not play a role, and the relationship with dyslipidaemia is unclear.^{10,11} Previous reports have suggested

* Corresponding author. Tel: +1 310 423 9680, Fax: +1 310 423 3522, Email: noel.baireymerz@cshs.org

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015. For permissions please email: journals.permissions@oup.com.

Table 1 Coronary Artery Vasospastic Disorders
Summit diagnostic criteria for vasospastic angina^a

Vasospastic angina diagnostic criteria elements
(1) Nitrate-responsive angina—during spontaneous episode, with at least one of the following:
(a) Rest angina—especially between night and early morning
(b) Marked diurnal variation in exercise tolerance—reduced in morning
(c) Hyperventilation can precipitate an episode
(d) Calcium channel blockers (but not β-blockers) suppress episodes
(2) Transient ischaemic ECG changes—during spontaneous episode, including any of the following in at least two contiguous leads:
(a) ST segment elevation ≥0.1 mV
(b) ST segment depression ≥0.1 mV
(c) New negative U waves
(3) Coronary artery spasm—defined as transient total or subtotal coronary artery occlusion (>90% constriction) with angina and ischaemic ECG changes either spontaneously or in response to a provocative stimulus (typically acetylcholine, ergot, or hyperventilation)

^a‘Definitive vasospastic angina’ is diagnosed if nitrate-responsive angina is evident during spontaneous episodes and either the transient ischaemic ECG changes during the spontaneous episodes or coronary artery spasm criteria are fulfilled. ‘Suspected vasospastic angina’ is diagnosed if nitrate-responsive angina is evident during spontaneous episodes but transient ischaemic ECG changes are equivocal or unavailable and coronary artery spasm criteria are equivocal.

that VSA is associated with the Raynaud’s phenomenon and migraine, as part of a generalized vasomotor disorder¹²; however, systematic studies have found the relationship tenuous.¹³ Japanese patients have been shown to have hyper-reactive vessels compared with Caucasians¹⁴ but it is uncertain whether this translates to a greater propensity for VSA.

Ischaemic electrocardiogram manifestations

In Prinzmetal’s original description,¹ spontaneous episodes of rest angina were associated with transient ST elevation that promptly resolved with short-acting nitrates. Subsequent studies have also demonstrated transient ST depression and U wave changes during spontaneous VSA episodes. If a spontaneous episode of rest angina is associated with transient ischaemic electrocardiogram (ECG) changes and there is no other cause identified for the ECG changes, then coronary artery spasm is presumed to be responsible and a definitive diagnosis of VSA may be made without formal documentation of coronary artery spasm (Table 1). However, documenting ischaemic ECG changes during spontaneous episodes of rest angina occurs infrequently so that coronary artery spasm provocative testing is often required.

Coronary artery spasm manifestations

Coronary artery spasm provocation testing has been clinically used for >40 years although in contemporary cardiology practice, it is

Table 2 Indications for provocative coronary artery spasm testing

Class I (strong indications)
• History suspicious of VSA without documented episode, especially if:
◦ Nitrate-responsive rest angina, and/or
◦ Marked diurnal variation in symptom onset/exercise tolerance, and/or
◦ Rest angina without obstructive coronary artery disease
◦ Unresponsive to empiric therapy
• Acute coronary syndrome presentation in the absence of a culprit lesion
• Unexplained resuscitated cardiac arrest
• Unexplained syncope with antecedent chest pain
• Recurrent rest angina following angiographically successful PCI
Class IIa (good indications)
• Invasive testing for non-invasive diagnosed patients unresponsive to drug therapy
• Documented spontaneous episode of VSA to determine the ‘site and mode’ of spasm
Class IIb (controversial indications).
• Invasive testing for non-invasive diagnosed patients responsive to drug therapy
Class III (contra-indications)
• Emergent acute coronary syndrome
• Severe fixed multi-vessel coronary artery disease including left main stenosis
• Severe myocardial dysfunction (Class IIb if symptoms suggestive of vasospasm)
• Patients without any symptoms suggestive of VSA

largely restricted to specialized centres. Multiple spasm testing protocols have been developed including non-invasive methods and these are discussed in detail in other papers.³ The discussion in this paper is restricted to the gold standard approach.

Method

The gold standard method for provocative spasm testing involves the administration of a provocative stimulus (typically intracoronary acetylcholine but alternatively intracoronary or intravenous ergonovine may be used) during invasive coronary angiography with the monitoring of patient symptoms, ECG and angiographic documentation of coronary artery spasm. A positive provocative test for coronary artery spasm must induce all of the following in response to the provocative stimulus: (i) reproduction of the usual chest pain, (ii) ischaemic ECG changes, and (iii) >90% vasoconstriction on angiography. The test result is considered equivocal if the provocative stimulus does not induce all three components. The consensus from the COVADIS symposium was that >90% vasoconstriction is the angiographic threshold to diagnose inducible spasm. Furthermore, this total/subtotal vasoconstriction may occur within the confines of one isolated coronary segment (focal spasm) or in ≥2 adjacent coronary segments (diffuse spasm).^{10,15} Validation studies have demonstrated a high sensitivity and specificity for both the ergonovine (91 and 97%, respectively¹⁶) and acetylcholine (90 and 99%, respectively¹⁷) protocols relative to the diagnosis of spontaneous VSA.

Risks

Non-invasive bedside provocative spasm testing has been associated with significant adverse events including death,¹⁸ because detection and alleviation of the induced spasm is delayed. In contrast, invasive provocative spasm testing allows rapid detection and treatment of the induced spasm. Accordingly, there are no reported deaths and a similar risk profile to other invasive coronary procedures,^{15,19,20} although there is 6.8% incidence of cardiac arrhythmias (i.e. comparable with that observed during spontaneous coronary artery spasm episodes).²⁰

Indications

Considering the risks associated with provocative spasm testing, the procedure should be performed by personnel experienced with the protocol in patients where the risk and benefits have been carefully evaluated. Table 2 outlines recommended indications for provocative spasm testing. These are ranked into the conventional Class I–III categories, based upon the relative risks and benefits of the investigation.

Conclusion

There are no universal diagnostic criteria for VSA, which has impaired the progress in understanding and diagnosing this disorder. Adoption of these diagnostic criteria will improve the clinical diagnosis of this condition and facilitate research in this field. Future directions for COVADIS involve the establishment of an international coronary vasomotor disorder clinical registry for diagnostic, prognostic, and therapeutic research.

Funding

Unrestricted medical education grant funding for COVADIS: Tohoku University, Japan; DFG, Germany; St Georges Hospital, University of London, UK; Barbra Streisand Women's Heart Center, Cedars-Sinai Medical Center, USA; The Hospital Research Foundation, Australia.

Conflict of interest: COVADIS has no relationship with industry. Author: Industry Relationship in past 2 years (all honoraria <\$10 000). C.N.B.M., Gilead (grant review), Japanese Circulation Society (speaker), Bristol Meyers Squibb (DSMB). J.F.B., Servier (speaker, conference), Bristol Meyers Squibb and Pfizer (speaker). J.C.K., Menarini (speaker, conference), Servier (Advisory Board). H.O., Japan Heart Foundation. P.O., Berlin-Chemie (speaker), Japanese Coronary Spasm Association (speaker). U.S., Berlin-Chemie (speaker). H.S., Japan Heart Foundation, Asaki Kasei Pharma (consultant).

References

1. Prinzmetal M, Kenamer R, Merliss R, Wada T, Bor N. Angina pectoris. I. A variant form of angina pectoris: preliminary report. *Am J Med* 1959;**27**:375–388.
2. JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with vasospastic angina (coronary spastic angina) (JCS 2008): digest version. *Circ J* 2010;**74**:1745–1762.
3. JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with vasospastic angina (Coronary Spastic Angina) (JCS 2013). *Circ J* 2014;**78**:2779–2801.
4. Montalescot G, Sechtem U, Achenbach S, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabaté M, Senior R, Taggart DP, van der Wall EE, Vrints CJ; ESC Committee for Practice Guidelines, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R,

- Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S; Document Reviewers, Knuuti J, Valgimigli M, Bueno H, Claeys MJ, Donner-Banzhoff N, Erol C, Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hämilos M, Hasdai D, Husted S, James SK, Kervinen K, Kolh P, Kristensen SD, Lancellotti P, Maggioni AP, Piepoli MF, Pries AR, Romeo F, Rydén L, Simoons ML, Sirnes PA, Steg PG, Timmis A, Wijns W, Windecker S, Yildirim A, Zamorano JL. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. *Eur Heart J* 2013;**34**:2949–3003.
5. Kaski JC, Crea F, Meran D, Rodriguez L, Araujo L, Chierchia S, Davies G, Maseri A. Local coronary supersensitivity to diverse vasoconstrictive stimuli in patients with variant angina. *Circulation* 1986;**74**:1255–1265.
6. Igarashi Y, Tamura Y, Suzuki K, Tanabe Y, Yamaguchi T, Fujita T, Yamazoe M, Aizawa Y, Shibata A. Coronary artery spasm is a major cause of sudden cardiac arrest in survivors without underlying heart disease. *Coron Artery Dis* 1993;**4**:177–185.
7. Da Costa A, Isaaz K, Faure E, Mourot S, Cerisier A, Lamaud M. Clinical characteristics, aetiological factors and long-term prognosis of myocardial infarction with an absolutely normal coronary angiogram: a 3-year follow-up study of 91 patients. *Eur Heart J* 2001;**22**:1459–1465.
8. Igarashi Y, Tamura Y, Tanabe Y, Fujita T, Yamazoe M, Shibata A. Angina-linked syncope and lack of calcium antagonist therapy predict cardiac arrest before definitive diagnosis of vasospastic angina. *Coron Artery Dis* 1994;**5**:881–887.
9. Lanza GA, Sestito A, Sgueglia GA, Infusino F, Manolfi M, Crea F, Maseri A. Current clinical features, diagnostic assessment and prognostic determinants of patients with variant angina. *Int J Cardiol* 2007;**118**:41–47.
10. Sato K, Kaikita K, Nakayama N, Horio E, Yoshimura H, Ono T, Ohba K, Tsujita K, Kojima S, Tayama S, Hokimoto S, Matsui K, Sugiyama S, Yamabe H, Ogawa H. Coronary vasomotor response to intracoronary acetylcholine injection, clinical features, and long-term prognosis in 873 consecutive patients with coronary spasm: analysis of a single-center study over 20 years. *J Am Heart Assoc* 2013;**2**:e000227.
11. Nobuyoshi M, Abe M, Nosaka H, Nosaka H, Kimura T, Yokoi H, Hamasaki N, Shindo T, Kimura K, Nakamura T, Nakagawa Y. Statistical analysis of clinical risk factors for coronary artery spasm: identification of the most important determinant. *Am Heart J* 1992;**124**:32–38.
12. Miller D, Waters DD, Warnica W, Szlachet J, Kreeft J, Theroux P. Is variant angina the coronary manifestation of a generalized vasospastic disorder? *N Engl J Med* 1981;**304**:763–766.
13. Nakamura Y, Shinozaki N, Hirasawa M, Kato R, Shiraishi K, Kida H, Usuda K, Ishikawa T. Prevalence of migraine and Raynaud's phenomenon in Japanese patients with vasospastic angina. *Jpn Circ J* 2000;**64**:239–242.
14. Pristipino C, Beltrame JF, Finocchiaro ML, Hattori R, Fujita M, Mongiardo R, Cianflone D, Sanna T, Sasayama S, Maseri A. Major racial differences in coronary constrictor response between Japanese and Caucasians with recent myocardial infarction. *Circulation* 2000;**101**:1102–1108.
15. Ong P, Athanasiadis A, Borgulya G, Vokshi I, Bastiaenen R, Kubik S, Hill S, Schäufele T, Mahrholdt H, Kaski JC, Sechtem U. Clinical usefulness, angiographic characteristics, and safety evaluation of intracoronary acetylcholine provocation testing among 921 consecutive white patients with unobstructed coronary arteries. *Circulation* 2014;**129**:1723–1730.
16. Heupler FA Jr, Proudfoot WL, Razavi M, Shirey EK, Greenstreet R, Sheldon WC. Ergonovine maleate provocative test for coronary arterial spasm. *Am J Cardiol* 1978;**41**:631–640.
17. Okumura K, Yasue H, Matsuyama K, Goto K, Miyagi H, Ogawa H, Matsuyama K. Sensitivity and specificity of intracoronary injection of acetylcholine for the induction of coronary artery spasm. *J Am Coll Cardiol* 1988;**12**:883–888.
18. Buxton A, Goldberg S, Hirshfeld JW, Wilson J, Mann T, Williams DO, Overlie P, Oliva P. Refractory ergonovine-induced coronary vasospasm: importance of intracoronary nitroglycerin. *Am J Cardiol* 1980;**46**:329–334.
19. Wei J, Mehta PK, Johnson BD, Samuels B, Kar S, Anderson RD, Azarbal B, Petersen J, Sharaf B, Handberg E, Shufelt C, Kothawade K, Sopko G, Lerman A, Shaw L, Kelsey SF, Pepine CJ, Merz CN. Safety of coronary reactivity testing in women with no obstructive coronary artery disease: results from the NHLBI-sponsored WISE (Women's Ischemia Syndrome Evaluation) study. *JACC Cardiovasc Interv* 2012;**5**:646–653.
20. Takagi Y, Yasuda S, Takahashi J, Tsunoda R, Ogata Y, Seki A, Sumiyoshi T, Matsui M, Goto T, Tanabe Y, Sueda S, Sato T, Ogawa S, Kubo N, Momomura S, Ogawa H, Shimokawa H. Clinical implications of provocation tests for coronary artery spasm: safety, arrhythmic complications, and prognostic impact: multicentre registry study of the Japanese Coronary Spasm Association. *Eur Heart J* 2013;**34**:258–267.

Appendix

Coronary Artery Vasospastic Disorders Summit Attendees

The following international participants attended the inaugural Coronary Artery Vasospastic Disorders Summit held in Amsterdam on 4–5 September, 2013.

Steering Committee

Bairey Merz, Noel—United States (Co-chair)
Beltrame, John—Australia (Co-chair)
Crea, Filippo—Italy
Kaski, Juan Carlos—United Kingdom
Ogawa, Hisao—Japan
Ong, Peter—Germany
Sechtem, Udo—Germany
Shimokawa, Hiroaki—Japan

Summit Attendees

Baek, Sang Hong—South Korea
Bugiardini, Raffaele—Italy
Camici, Paolo—Italy
Conti, Richard—United States
Di Fiore, David—Australia
Lanza, Gaetano—Italy
Marzilli, Mario—Italy
Maseri, Attilio—Italy
Matsumoto, Yasuharu—Japan
Mehta, Puja—United States
Nihei, Taro—Japan
Nishimiya, Kensuke—Japan
Sueda, Shozo—Japan
Tremmel, Jennifer—United States
Uzuka, Hironori—Japan

The Coronary Artery Vasospastic Disorders Summit was supported by funds from the German Research Foundation and the Japan Heart Foundation.